310430-79-6

Usage

Derivative of pyrrole

A five-membered aromatic heterocycle with a nitrogen atom The compound is based on the pyrrole structure, which is a five-membered ring containing one nitrogen atom and four carbon atoms, known for its aromatic properties.

Amide functional group

Contains an amide group The compound has an amide group (C=O) bonded to the pyrrole ring, which is known for its polar and hydrogen bonding properties.

Amino group

Contains an amino group The compound has an amino group (NH2) attached to the pyrrole ring, which is a basic and nucleophilic functional group.

Methyl group

Contains a methyl group The compound has a methyl group (CH3) attached to the pyrrole ring, which is an alkyl group consisting of one carbon and three hydrogen atoms, contributing to the compound's steric and electronic properties.

9CI designation

Listed in the Chemical Abstracts Service (CAS) database The 9CI designation indicates that the compound is registered in the CAS database, which is a comprehensive resource for chemical substances and their properties, reactivity, and uses.

Research focus

Properties, reactivity, and potential uses Studies and research on 1H-Pyrrole-2-carboxamide,1-amino-4-methyl-(9CI) may focus on understanding its physical and chemical properties, reactivity with other substances, and potential applications in various industries, such as pharmaceuticals and organic synthesis.

Upstream product

• 616-43-3 3-methylpyrrole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 310430-81-0 6-methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one 

Relevant academic research and scientific papers

PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, X1, X2, m, and n are described herein.

Pyrrolotriazine inhibitors of kinases

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template

The pyrrolo[2,1-f][1,2,4]triazine nucleus was identified as a novel kinase inhibitor template which effectively mimics the well-known quinazoline kinase inhibitor scaffold. Attachment of a 4-((3-chloro-4-fluorophenyl)amino) substituent to the template provided potent biochemical inhibitors of the tyrosine kinase activity of EGFR, as well as inhibition of cellular proliferation of the human colon tumor cell line DiFi. Attachment of a 4-((3-hydroxy-4-methylphenyl)amino) substituent provided potent inhibitors of VEGFR-2 which also showed effects on the VEGF-dependent proliferation of human umbilical vein endothelial cells. Biological activity was maintained with substitution at positions 5 or 6, but not 7, suggesting that the former positions are promising sites for introducing side chains which modulate physicochemical. properties. Preliminary inhibition studies with varying ATP concentrations suggest that, like the quinazoline-based kinase inhibitors, the pyrrolotriazine-based inhibitors bind in the ATP pocket.